Search academic texts

Information × Registration Number 0219U000975, 0117U000406 , R & D reports Title Develop methods chemoradiotherapy patients with secondary (metastatic) cancer of the vagina using various sources of radiation popup.stage_title Head Ivankova Valentina Stepanovna, Доктор медичних наук Registration Date 21-03-2019 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 During the second stage of research, the optimal methods of chemo-ray therapy for patients with metastatic cancer of the vagina using cytostatic drugs (fluorouracil, cisplatin) as radiomodifiers during conformal radiotherapy and high-energy 60Co and 192Ir-brachytherapy at different regimens were determined; The estimation of direct results (efficiency and toxicity) of developed methods of chemo-ray therapy in patients with secondary (metastatic) vaginal cancer is given. Inspection and treatment of 63 patients with secondary (metastatic) cancer of the vagina received at the 1st stage of the course of PPT conformal PA on the apparatus of the linear electron accelerator (CLP) "Clinac-2100 CD" on the pelvic region (tumor and its regional distribution region) was administered One dose cell (ROD) of 2.0 Gy to a total focal dose (OOD) of 30-40 Gy, taking into account the dose of irradiation given in the previous radiotherapy. At stage II of the PTC course, all groups were subjected to high-energy (HDR) intracavitary brachytherapy (BT) with sources 192Ir (GammaMed plus IX) or 60Со (GyneSource device). Depending on the source and mode of exposure, the patients are divided into two main and control groups. The first main group was 21 patients with secondary (metastatic) cancer of the vagina, which HDR BT was operated by 192Ir sources according to the regimen: ROD = 3 Gy x 3 g / week. In the II main group included 20 patients with secondary (metastatic) cancer of the vagina, which HDR BT conducted sources 192Ir by regimen: ROD = 5 Gy x 2 p / week. The control group consisted of 22 patients with secondary (metastatic) cancer of the vagina, which HDR BT was operated by sources 60Co according to the regimen: ROD = 5 Gy x 2 g / week. Throughout the course of PPT, patients in all groups received fluorouracil orally 400 mg x 2 times a day and cisplatin 50 mg 1 time per week intravenously drops 4-6, to DM 200-300 mg. The analysis of direct efficacy and toxicity of the developed methods of radiotherapy for patients with secondary (metastatic) vaginal cancer testifies to their effectiveness and absence of excessive toxicity. It was established that the use of the 192Ir source in HDR BP in developed regimens in patients with major groups contributes to the reduction of toxic manifestations of chemo-radiation therapy (epithelium, cystitis, rectum / enterocolitis) and somewhat increases the direct efficiency (regression of tumor) of chemo-radiation therapy, as compared with the control group, where the patients performed HDR BT with sources 60Co. Thus, in patients with the main group I, the complete regression (PR) of the tumor was registered at 19.0%, partial regression (CR) of the tumor - at 38.1%, stabilization of the process - in 42.9% of patients; in patients of the II main group, PR tumors were observed in 20,0%, CR in the tumor - 40,0%, stabilization of the process - in 40,0% of patients; in the control group, respectively, 18.2%, 36.4% and 45.4% of patients with secondary (metastatic) vaginal cancer. Product Description popup.authors Іванкова Валентина Степанівна Бакай Ольга Олексіївна Барановська Лідія Михайловна Галяс Оксана Вікторівна Палій Максім Ігорович Скоморохова Тетяна Володимирівна Хруленко Тетяна Валерівна popup.nrat_date 2020-04-02 Close